Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Deutsche Boerse AG  >  Epigenomics AG    ECX   DE000A11QW50

EPIGENOMICS AG (ECX)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Epigenomics : Supervisory Board of Epigenomics AG Appoints Albert Weber as Executive Vice President Finance and a Member of the Management Board (Vorstand)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/29/2017 | 09:45pm CET

DGAP-News: Epigenomics AG / Key word(s): Change of Personnel
Supervisory Board of Epigenomics AG Appoints Albert Weber as Executive Vice President Finance and a Member of the Management Board (Vorstand)

29.11.2017 / 21:41
The issuer is solely responsible for the content of this announcement.


Press release

Supervisory Board of Epigenomics AG Appoints Albert Weber as Executive Vice President Finance and a Member of the Management Board (Vorstand)

Berlin (Germany) and Germantown, MD (U.S.A.), November 29, 2017 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), announced today that the Supervisory Board appointed Albert Weber Executive Vice President of Finance effective January 1, 2018. Mr. Weber, who has worked at Epigenomics for the past seventeen years, will become a member of the Executive Board of Epigenomics and continue to oversee the company's financial, accounting and controlling departments.

Mr. Weber (54), has more than 25 years of corporate finance experience including the last seventeen years at Epigenomics. Prior to this recent appointment Mr. Weber was the Senior Vice President of Finance, Accounting and Controlling for Epigenomics. Prior to joining the company, Albert served as Manager Controlling of Pironet AG, a Cologne based IT start-up and previously at EMI Group Germany as the Manager Treasury and Corporate Accounting. Mr. Weber has experience in capital raises, all corporate finance functions and IPO's. He has a degree in Business Administration from Cologne University and is certified in IFRS accounting.

Heino von Prondzynski, Chairman of the Supervisory Board, stated: "The Supervisory Board is very happy to recognize Albert's hard work and dedication to Epigenomics by adding him the Executive Board. Mr. Weber's financial experience will be a valued benefit to the Executive Board as the company prepares for the next stage of growth."

"I am excited to join the Executive Board," said Mr. Weber. "I've been with Epigenomics for seventeen years and I'm truly excited about the amazing opportunity in front of the company. I look forward to helping the organization transform the colorectal screening market."

About Epigenomics

Epigenomics is a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology. The company develops and commercializes diagnostic products across multiple cancer indications with high medical need. Epigenomics' lead product, Epi proColon, is a blood-based screening test for the detection of colorectal cancer. Epi proColon has received approval from the U.S. Food and Drug Administration (FDA) and is currently marketed in the United States, Europe, and China and selected other countries. Epigenomics' second product, Epi proLung(R), is in development as a blood-based test for lung cancer detection.

For more information, visit www.epigenomics.com.

Contact:
Epigenomics AG, Investor Relations, Peter Vogt, Geneststrasse 5, 10829 Berlin, Tel +49 (0) 30 24345 386, Fax +49 (0) 30 24345 555, E-Mail: [email protected]

Epigenomics legal disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.



29.11.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Epigenomics AG
Geneststraße 5
10829 Berlin
Germany
Phone: +49 30 24345-0
Fax: +49 30 24345-555
E-mail: [email protected]
Internet: www.epigenomics.com
ISIN: DE000A11QW50
WKN: A11QW5
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange

 
End of News DGAP News Service

634075  29.11.2017 

fncls.ssp?fn=show_t_gif&application_id=634075&application_name=news&site_id=zonebourse

© EQS 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on EPIGENOMICS AG
11/29 EPIGENOMICS : Supervisory Board of Epigenomics AG Appoints Albert Weber as Execu..
11/21 EPIGENOMICS : announces recent payment decision by CMS
11/21 EPIGENOMICS : announces recent payment decision by CMS
11/15 EPIGENOMICS : Announces 2017 Third Quarter and Nine Months Financial Results
11/13 EPIGENOMICS AG : Preliminary announcement of the publication of quarterly report..
11/08 EPIGENOMICS AG : Appointment of Director Reimbursement and Medical Affairs
11/08 EPIGENOMICS AG : Appointment of Director Reimbursement and Medical Affairs
11/05 EPIGENOMICS : Supervisory Board of Epigenomics AG Appoints Dr. Jorge Garces as P..
11/05 EPIGENOMICS : Supervisory Board of Epigenomics AG Appoints Dr. Jorge Garces as P..
10/19 EPIGENOMICS AG : Release according to Article 26, Section 1 of the WpHG [the Ger..
More news
News from SeekingAlpha
11/16 Epigenomics AG 2017 Q3 - Results - Earnings Call Slides
11/15 Epigenomics' (EPGNF) CEO Gregory Hamilton on Q3 2017 Results - Earnings Call ..
11/15 Epigenomics reports Q3 results
08/12 Epigenomics' (EPGNF) CEO Gregory Hamilton on Q2 2017 Results - Earnings Call ..
08/09 Epigenomics reports Q2 results
Financials (€)
Sales 2017 3,15 M
EBIT 2017 -13,4 M
Net income 2017 -13,9 M
Finance 2017 35,5 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 16,5x
EV / Sales 2018 2,80x
Capitalization 87,6 M
Chart EPIGENOMICS AG
Duration : Period :
Epigenomics AG Technical Analysis Chart | ECX | DE000A11QW50 | 4-Traders
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 6,11 €
Spread / Average Target 69%
EPS Revisions
Managers
NameTitle
Gregory K. Hamilton Chief Executive Officer
Jorge A. Garces President & Chief Scientific Officer
Heino von Prondzynski Chairman-Supervisory Board
Uwe Staub Chief Operating Officer
Günther Reiter Vice Chairman-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
EPIGENOMICS AG-8.00%103
MIRACA HOLDINGS INC.-8.94%2 420
GENSCRIPT BIOTECH CORP183.78%2 328
BEIJING STRONG BIOTECHNOLOGIES INC--.--%1 221
SEEGENE INC--.--%750
IOVANCE BIOTHERAPEUTICS INC20.14%636